Atypical Hemolytic Uremic Syndrome (aHUS) Epidemiology

Key Highlights

• Atypical hemolytic uremic syndrome (aHUS) is a disease that causes abnormal blood clots to form in small blood vessels in the kidneys. These clots can cause serious medical problems if they restrict or block blood flow, including hemolytic anemia, thrombocytopenia, and kidney failure.
• The most common symptoms of aHUS are confusion, stroke, seizure, heart attack, high blood pressure, formation of blood clots in the kidney, heart, or other organs, nausea and vomiting, abdominal pain, and kidney damage.
• Most cases of aHUS are genetic, although some may be acquired due to autoantibodies or for unknown reasons (idiopathic). aHUS may become chronic, and affected individuals may experience repeated episodes of the disorder. Individuals with aHUS are much more likely to develop chronic serious complications such as severe high blood pressure (hypertension) and kidney (renal) failure.
• The diagnostic test of aHUS includes a complete blood count (CBC) test, which is used to measure the red blood cell and platelet count. Kidney health can be measured by a test called estimated glomerular filtration rate (eGFR) which is calculated using the creatinine level, age, sex, and race.
• In 2023, total diagnosed cases of aHUS in the United States were nearly 2,500 cases.
• aHUS is more common in adolescents and adults population than in pediatric. In the United States, there were approximately 2,200 and 400 cases of adolescent adults and pediatric patients, respectively, in 2023.

Report Summary

• The report offers extensive knowledge regarding the epidemiology segments and predictions, presenting a deep understanding of the potential future growth in diagnosis rates, disease progression, and diagnostic guidelines. It provides comprehensive insights into these aspects, enabling a thorough assessment of the subject matter.
• The report also encompasses a comprehensive analysis of Atypical Hemolytic Uremic Syndrome, providing an in-depth examination of its historical and projected data from 2021 to 2034. It includes detailed assumptions and the underlying rationale for the methodology.
• The report also encompasses a comprehensive analysis of Atypical Hemolytic Uremic Syndrome, providing an in-depth examination of its historical and projected data from 2021 to 2034. It includes detailed assumptions and the underlying rationale for the methodology.
• The report includes qualitative insights that provide an edge in understanding trends through SWOT analysis and expert insights/KOL views, including experts from various hospitals and prominent universities, patient journey that help shape and drive the Atypical Hemolytic Uremic Syndrome landscape.

The table given below further depicts the key segments provided in the report:

Atypical Hemolytic Uremic Syndrome: Disease Understanding 

Atypical Hemolytic Uremic Syndrome Overview, and Diagnosis

aHUS is an extremely rare disease characterized by low levels of circulating red blood cells due to their destruction (hemolytic anemia), low platelet count (thrombocytopenia) due to their consumption, and the inability of the kidneys to process waste products from the blood and excrete them into the urine (acute kidney failure), a condition known as uremia.

Hemolytic anemia occurs when RBC undergoes hemolysis faster than normal. In aHUS, RBCs can break apart as they squeeze past clots within small blood vessels. If cells are destroyed faster than the body can replace them, it leads to anemia. As a result of clot formation in small blood vessels, patients experience kidney damage and acute kidney failure, leading to end-stage renal disease (ESRD) in about half of all cases.

Diagnosing aHUS is complicated by the fact that it is more challenging to establish without a family history of the disorder. The diagnostic criteria associated with aHUS are hemolytic anemia (anemia in the presence of broken red blood cells), low platelet count (thrombocytopenia), and kidney dysfunction.

Atypical Hemolytic Uremic Syndrome Epidemiology

The aHUS epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases, diagnosed cases, age-specific cases, and treated cases of aHUS in the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2021 to 2034.

• Among the 7MM, the United States accounted for the highest number of prevalent cases of aHUS in 2023, nearly 3,500 cases. These cases are anticipated to increase by 2034.
• In the United States, Adolescents and adults population accounted for the ~80% of diagnosed cases in 2023. 
• Among EU4 and the UK, Germany accounted for the highest number of prevalent cases in 2023, while Spain accounted for the least.

KOL Views

To stay abreast of the latest trends we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research.

Our team of analysts at Delveinsight connected with more than 15 KOLs across the 7MM. We contacted institutions. By obtaining the opinions of these experts, we gained a better understanding of the current epidemiology patterns in the Atypical Hemolytic Uremic Syndrome landscape, which will assist our clients in analyzing the overall epidemiology scenario.

Atypical Hemolytic Uremic Syndrome Report Insights

• Patient Population
• Atypical Hemolytic Uremic Syndrome Epidemiology Segmentation
• Existing Epidemiological Trends and Predictions

Atypical Hemolytic Uremic Syndrome Report Key Strengths

• Eleven-year Forecast
• The 7MM Coverage 
• Atypical Hemolytic Uremic Syndrome Epidemiology Segmentation

Atypical Hemolytic Uremic Syndrome Report Assessment

• Epidemiological Trends and Disease Progression
• Qualitative Analysis (SWOT, Expert Insights, Unmet Needs)

Key Questions

• Would there be any changes observed in the epidemiological trends of Atypical Hemolytic Uremic Syndrome?
• Will there be improvements in the understanding of Atypical Hemolytic Uremic Syndrome progression?
• Would research advances lead to better epidemiological data for Atypical Hemolytic Uremic Syndrome?
• How will the diagnostic testing space impact the epidemiology of Atypical Hemolytic Uremic Syndrome?
• How will the prevalence and incidence of Atypical Hemolytic Uremic Syndrome evolve in the coming years?

Reasons to buy

• Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the change in Atypical Hemolytic Uremic Syndrome cases in varying geographies over the coming years.
• A detailed overview of total prevalent cases of Atypical Hemolytic Uremic Syndrome, total diagnosed cases of Atypical Hemolytic Uremic Syndrome, age-specific cases of Atypical Hemolytic Uremic Syndrome, total treated cases of Atypical Hemolytic Uremic Syndrome is included.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the treatment-eligible patient pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.